Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘acute leukemia’

We have been following the progress of small molecule inhibitors targeting the menin-chromatin interaction which leads to NPM1 mutated or MLL-rearranged acute leukemias for over a year now.

In the beginning there was Syndax and Kura Oncology, now there’s a growing list of other companies entering this niche, both big and small.

In this post we take a look at what’s new in the landscape and also explore Syndax’s updated phase 1 data announced this morning.

Where are things headed and what can we learn about the latest data drop?

To learn more about the Menin NPM1-MLLr niche and get a heads up on our oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

After the snow flurry in Atlanta that induced much panic and minor frustration in equal measure after the trials and tribulations of a tiring travel day with delays and cancellations galore. Then you see attendees waking up to a veritable winter wonderland in the south:

Meanwhile, things soon settled down somewhat and life got back to normal at the American Society of Hematology (ASH), as this quick time lapse that 3NT recorded showed down the main thoroughfare :

It’s time for our annual meeting daily highlights and lowlights because after all, oncology R&D is not a rose tinted garden and thus not every session or compound you highlight pre-conference will turn out as expected and sometimes, there are pleasant surprises that few see coming so you could end up at sixes and sevens if you don’t watch out…

To get a heads up and insights from ASH, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!